Phosphorylation and compactness of neurofilaments in multiple sclerosis: Indicators of axonal pathology by Petzold, A et al.
Phosphorylation and compactness of
neurofilaments in multiple sclerosis:
indicators of axonal pathology
Axel Petzold (corresponding author)∗
Djordje Gveric †
Mike Groves ‡
Klaus Schmierer §
Donna Grant ¶
Miles Chapman ‖
Geoffrey Keir ∗∗
Louise Cuzner ††
Edward J. Thompson ‡‡
June 10, 2008
Disclaimers: The authors have nothing to disclose.
Financial support: KS and DG were supported by the Wellcome Trust.
Word count abstract: 215
Word count main text: 3670
Number of text pages: 15
Number of Figures: 9
Number of Tables: 2
∗Department of Neuroinflammation, Institute of Neurology, Queen Square, London,
WC1N 3BG, United Kingdom. Fax: +44 20 7837 8553, E-mail: a.petzold@ion.ucl.ac.uk
†Department of Neuroinflammation, Institute of Neurology
‡Department of Pathology, Institute of Neurology
§Department of Neuroinflammation, Institute of Neurology
¶Department of Neuroinflammation, Institute of Neurology
‖Department of Neuroinflammation, Institute of Neurology
∗∗Department of Neuroinflammation, Institute of Neurology
††Department of Neuroinflammation, Institute of Neurology
‡‡Department of Neuroinflammation, Institute of Neurology
1
NfH phosphoforms in MS 1
Abstract
Aims: Axonal pathology extends to the axonal cytoarchitecture
leaving its signature on axoskeletal proteins. This study investigated
whether neurofilament (NfH) phosphorylation would relate to the the
dynamics of axonal pathology in multiple sclerosis (MS).
Methods: NfH phosphoforms (SMI32, SMI34, SMI35) were quan-
tified by ELISA from microdissected samples of control and MS brain
and spinal cord. Individual axons were analysed by electronmicroscopy,
densitometrically and morphologically in adjacent tissue sections. Ex-
periments were carried out pre- and post enzymatic dephosphoryla-
tion.
Results: In control tissue a rostro–caudal gradient of NfH indi-
cated an increase in axonal density from the brain gray matter to-
wards the spinal cord. The highest levels of phosphorylated and
hyperphosphorylated NfH were found in acute lesions of brain and
spinal cord, in contrast to chronic lesions where levels were lower
than in white matter, consistent with axonal loss. Dephosphorylated
NfH was higher, but less densly packed in MS white matter axons
compared to control tissue.
Conclusions: The findings suggest that a less organised/compact
axoskeleton or impaired axonal transport may represent an early sign
of axonal pathology within the normal appearing white matter in MS.
Subsequent a proportional increase of dephosphorylated NfH, aber-
rant phosphorylation and/or aggregation may occur whilst the protein
is transported through the white matter towards the MS plaque, where
hyperphosphorylated NfH dominates.
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jury
Abbreviations: AL = acute lesion, ALP = alkaline phosphatase, BSP =
brain–specific proteins, CL = chronic lesion, CNS = central nervous sys-
tem, CTRL = control group, EDSS = Expanded Disability Status Scale,
ELISA = enzyme linked immunoabsorbant assay, EM = electron microscopy,
GM = gray matter, IQR = interquartile range, MS = multiple sclerosis,
NAWM = normal–appearing white matter, Nf = neurofilament, NfH = neu-
rofilament heavy chain, NfL = neurofilament light chain, PP = primary pro-
gressive, RR = relapsing remitting, SAL = subacute lesion, SAPK = stress–
activated protein kinase, SP = secondary progressive, WM = white matter.
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1 Introduction
Multiple sclerosis (MS) is an inflammatory demyelinating disease in which
axonal loss,1–3 thought to be the main pathological substrate for irreversible
disability, is the dominant pathological feature of the degenerative phase
of the disease (reviewed in4–6). In chronic MS patients about 50% of
demyelinated spinal cord axons showed an abnormally fragmented axo-
plasm compared to about 4.8% of myelinated axons.7 The finding was
attributed to altered neurofilament (Nf) spacing. Neurofilaments are pro-
teins specifically designed for post–translational modifications within the
axonal compartment. Neurofilament phosphorylation increases Nf spac-
ing and thereby axonal calibre.8–10 The distinguishing feature of the Nf
heavy chain (NfH) is its long tail with multiple KSP repeats acting as the
main phosphorylation sites (see Figure 1). Phosphorylation of the NfH
KSP repeats is influenced by Ca2+ influx, glutamate, NGF and fibrin.8,11–14
All of these mechanisms feature in the pathophysiology of MS. The pattern
of NfH phosphorylation in staged lesions of MS and control brain tissue is
not known.
In the present study we investigate the quantitative distribution of NfH
phosphoforms in microdissected brain and spinal cord tissue with the aim
of (1) outlining the topography of NfH phosphoforms in control tissue and
(2) comparing NfH phosphoforms from control tissue with the lesion–specific
NfH phosphoform distribution in MS tissue.
2 Material and methods
Subjects Patients with secondary MS according to the Poser criteria and
age–matched controls were included in the study. All MS patients were
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classified as secondary progressive with significant disability (EDSS 9–
10).15 Tissue was kindly provided by the Neuroresource Tissue Bank at
the Institute of Neurology. We have previously published on this cohort with
regard to glial biomarkers16 and the fibrinolytic system in brain tissue.15,17
Tissue sampling has been extended and spinal cord tissue was included
to enable a more global and systematic assessment in the present study.
In total, 77 snap–frozen tissue blocks (0.5–1cm3) were analysed.
Immunocytochemistry For immunocytochemistry, 10 µm cryostat sec-
tions were immunoperoxidase–stained with antibodies directed against SMI32,
SMI34 and SMI35 (Sternberger Monoclonals Inc., Lutherville, USA), GFAP,18
14E for oligodendrocytes and reactive astrocytes.19 Cryostat sections
were fixed in methanol (-20◦C, 10 min), incubated with primary antibody
overnight (4◦C) and stained using a three-step peroxidase method.20 Ad-
jacent sections were incubated with 0 mU (control), 10 mU, 100 mU or
1000 mU alkaline phosphatase (Sigma, P4252) in Tris-HCl buffer (100 mM
Tris, pH 8.1 with 1% Triton X-100), at room temperature for 18 hours prior
to immunostaining as described.21 Omission of primary antibodies and
the application of affinity purified rabbit (Dako), goat (Sigma) and mouse
IgG (Sigma) were used as controls at the same protein concentrations as
the appropriate primary antibodies. Images were photgraphed on a Leitz
DMRB microscope using a 1/125 exposure time on a Nikon Coolpix 995
camera (3.34 megapixels).
Lesion classification Unfixed post–mortem brain tissue was histologi-
cally classified into normal–appearing white matter (NAWM), acute lesions
(AL), chronic lesions (CL) and gray matter (GM) from MS patients using
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previously published criteria.22 Adjacent pieces of each type of tissue were
excised and homogenised as described.23 This study did not include re-
myelinated lesions or cortical demyelination.
Electron microscopy Standard protocols were used for electron microscopy
(EM). In brief, post–mortem brain tissue samples were taken from the
frontal periventricular white matter and fixed for 1 hour in 4% glutaralde-
hyde in 0.1 M sodium cacodylate buffer (pH 7.4). The samples were then
cut into 1 mm cubes, washed in PBS and processed into araldite CY 212
for EM. Ultrathin sections were cut from the surface of the tissue, stained
with uranyl acetate and lead citrate, and examined at 80 kV.
Image analysis Images were analysed on a LINUX workstation using
the GNU Image Manipulation Program (GIMP is distributed under the GNU
General Public License and can be obtained free of charge from www.gimp.org).
For densitometric analysis sections of individual axons were used. For
each axon, the diameter was measured using the number of pixels as an
arbitrary unit. Next, a histogram of the pixel intensity was obtained on a
grey–scale ranging from 0 (black) to 255 (white). The mean pixel intensity
(±SD), range and the absolute pixel number per axon were recorded. Be-
cause background intensity varied between slides, the mean background
intensity was subtracted from the mean intensity for each axonal mea-
surement. The estimated optical density (OD), was then expressed as the
ratio of 1 to the mean pixel intensity as an arbitrary unit. Finally, the ratio
of OD to axonal diameter was used in order to express the compactness
of axonal NfH.
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Protein extraction Snap-frozen blocks of brain tissue from MS and con-
trol cases of between 0.5 g and 1 g wet weight, were cut and re-suspended
at 1:5 g/mL in Tris-HCl buffer (100 mM Tris, pH 8.1 with 1% Triton X-
100). A protease inhibitor cocktail (Sigma, P 8340) was added in a di-
lution 1:100. Samples were homogenised on ice by sonication, triturated
3 times through 19 and 21 gauge needles and spun at 20,000 g. In or-
der to de-lipidise the sample diisopropyl ether was added. After extensive
mixing, the sample was spun at 20,000 g. The supernatant was covered
by a myelin layer. A needle was put through the myelin layer and only the
supernatant drawn up into a 1 mL syringe. The myelin layer and pellet
were decanted. The supernatant was aliquotted into 2 portions.
Dephosphorylation It has been suggested that dephosphorylation un-
covers epitopes particularly accessible to SMI32, which are otherwise hid-
den21 (Figure 1). Therefore one aliquot of the tissue homogenate was
subjected to enzymatic dephosphorylation by using alkaline phosphatase
(ALP, Sigma, P4252) which dephosphorylates Nf.8
Barbitone buffer was selected for NfH incubation with ALP because it
is inert to enzyme activity [24, p. 831]. The optimum pH for the different
alkaline phosphatase isoforms varies from about 8.5 to 10.5, thus enabling
direct incubation into the sample buffer (pH 8.9).25
Western- and Immunoblotting A tris–acetate gel (3–6%, NuPage) was
used for Western- and immunoblotting. The gel was loaded with 5µL of
molecular weight markers (Invitrogen, Novex P/N57318 for the Coomasie
stain and MagicMark XP P/N LC5602 for Chemiluminescence). Thirty mi-
crolitre of sample were loaded per lane. The sample contained either pu-
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rified NfH (12.5 µg/mL), purified NfH (12.5 µg/mL) together with ALP (50
µg/mL) or ALP alone (50µg/mL). The gel was run for 1.5 hours using Tris-
Acetate SDS running buffer (Novex, LA0041) at 150 V. The gel was cut in
three parts: lanes 1-4 for Coomasie stain, lanes 5-7 for incubation with the
SMI34 antibody and lanes 8-10 for incubation with the SMI32 antibody. For
the immunoblot proteins were transferred onto nitrocellulose (Novex trans-
fer buffer, NP00061, at 25 V for 2 hours). The membranes were blocked
in 5% skimmed milk (barbitone buffer) for 1 hour. The membranes were
washed and incubated in 0.1% skimmed milk (barbitone buffer) with mon-
oclonal mouse anti-NfH antibodies (SMI34 1:1000, SMI32 1:1000) at 4◦C
overnight. The membranes were washed 6 times for 10 minutes, incubated
with HRP–labeled rabbit anti mouse (DAKO, P0260, 1:1000) and washed
as before. The membranes were incubated with the chemiluminescence
substrate (SuperSingal West Pico, Thermo Scientific, #34078) for 5 min-
utes. The dried membranes were visualised on a AlphaEase FluorChem
SP CCD camera (20 seconds for SMI34 and 7 minutes for SMI32).
The Coomasie stain shows a band at approximately 200 kDa for phos-
phorylated NfH (lane 2 in Figure 2 A). ALP gives a strong band at≈ 31 kDa
(lanes 3 and 4). ALP dephosphorylated NfH shows a band at ≈ 190 kDa
(lane 4). The immunoblots show that SMI34 binds selectively to phospho-
rylated NfH (lane 5) and SMI32 to dephosphorylated NfH (lane 8). There
is no cross-creativity of either antibody with ALP.
Assays Levels of NfH phosphoforms were quantified using an in–house
ELISA technique as described.25 All samples were analysed in duplicates
and repeated if the error between duplicates exceeded 10%. The mono-
clonal antibodies SMI32, SMI34 and SMI35 were purchased from Stern-
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berger Monoclonals Inc. (these antibodies are now supplied by Covance).
Figure 1 summarises the antibody binding properties.
As proof–of–principle HPLC–purified bovine NfH (Affiniti Research Prod-
ucts) was incubated with ALP at different concentrations ranging from 0.2
mU to 125 mU for 2 hours at 37◦C (pH 10.3). ALP denatures above
56◦C, therefore incubation for 10 minutes at 60◦C was used for stopping
the enzymatic reaction. The untreated control samples were subjected
to the same procedure and incubated with an equal volume of sample
buffer. The effect enzymatic dephosphorylation has on covering the epi-
topes recognised by SMI34 and uncovering the epitopes recognised by
SMI32 is shown in Figure 2. Complete dephosphorylation of the phospho–
epitope recognised by SMI34 was achieved following dephosphorylation
with 2 mU ALP. However unmasking of the non–phosphorylated epitope
recognised by SMI32 required a higher concentration of ALP with approx-
imately 75 mU. For this reason the patients’ samples were incubated with
100 mU of ALP for 18 hours at room temperature. Figure 2 B demon-
strates that the degree of dephosphorylation was sufficient to completely
mask the epitope recognised by SMI34 (shown in the immunoblot in Fig-
ure 2 A) from the spinal cord homogenates. All aliquots were then stored
at -70 ◦C until further analysis.
Total protein was determined using the Bio–Rad Protein assay (Bio–
Rad, Hemel Hempstead, UK).
Data analysis All statistical and data analyses were carried out using
SAS (version 9.1, SAS Institute, Inc., Cary, North Carolina, USA). The 2–
tailed non-parametric two–sample exact Wilcoxon rank-sum test was used
for comparing two groups and a 2–tailed two–way unbalanced ANOVA
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(general linear model, GLM) for more than two groups. If significance
was based on small numbers (n<10), the results were also subjected to
Fisher’s exact test comparing proportions of samples above or below cut–
off. The cut–off was defined as the 100% cumulative frequency of the
subgroup with the lowest values. Trend analysis was done using Mantel–
Haenzels χ2 test. Correlation analysis was performed using the Spear-
man Correlation Coefficients followed by the Bonferroni correction in case
of multiple analyses. A p–value of < 0.05 was accepted as significant
if shown on the discrete (GLM and post–hoc) and the categorical level
(Fisher’s exact test). The p–values for the GLM post–hoc analysis are
given in the Tables and for Fisher’s exact test in the Figures.
3 Results
The patients’ characteristics are summarised in Table 1. There were no
significant differences in the age distribution or the post–mortem interval,
but there were more females in the MS group than in the control group
(p<0.05).
There was no correlation for any of the NfH phosphoforms with either
the post–mortem interval, the age or the disease duration.
The effect of dephosphorylation (see Figure 1) is demonstrated by im-
munocytochemistry in Figure 3. In untreated MS tissue mainly axonal
end–bulbs stained for SMI32 (Figure 3 A). Most end–bulbs were observed
in the AL, some in the NAWM adjacent to the lesion and only very few in
NAWM distal to lesions. Treatment with ALP uncovered previously hidden
epitopes21 and revealed a much richer network of axons (Figure 3 B) in-
volving the entire NAWM. In contrast, staining for SMI35 which recognises
phosphorylated epitopes on NfH was clearly reduced in NAWM after de-
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phosphorylation and to a lesser degree in AL (Figure 3 C, D). At the border
of chronic lesions (CL), treatment with ALP did reduce staining for SMI35
to a lesser extend (Figure 4 C, D), giving the impression that phosphory-
lated NfH might “pile up” (Figure 4 D). As before enzymatic dephosphory-
lation did increase the staining for non–phosphorylated NfH (Figure 4 A,
B), again giving the impression that it may “pile up” at the border of the CL
(Figure 4 B).
As expected from the immunocytochemical data, treatment with ALP
almost abolished the levels of phosphorylated and hyperphosphorylated
NfH in the ELISA (data not shown) and considerably increased the lev-
els of dephosphorylated NfH. For this reason the further analysis will only
consider data from untreated samples for hyper-/phosphorylated NfH and
ALP treated samples for data on dephosphorylated NfH (see Table 2).
Topography of NfH phosphoforms in control tissue
NfH phosphoform distribution In control tissue we observed a rostro–
caudal gradient of phosphorylated (Figure 5 and Table 2 A) and dephos-
phorylated NfH (Table 2 B) with increasing concentrations from brain gray
matter, to brain white matter, to spinal cord white matter. This trend was
significant for phosphorylated NfH (M-H χ2=12.37, p<0.01, Table 2 A) and
dephosphorylated NfH (MHχ2=7.4, p<0.01, Table 2 B).
Overall, the rostro–caudal gradient was most marked for phosphory-
lated NfH in control tissue (F2,16=5.53, p<0.01) and to a lesser degree for
dephosphorylated NfH (F2,16=4.17, p<0.05). The phosphorylated NfH lev-
els were about 3 to 15–fold higher in control spinal white matter compared
to control brain gray matter or control brain white matter (p<0.05, p<0.01,
respectively). Thus the percentage of phosphorylated NfH to the total sol-
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uble protein corresponds to 0.04% in the grey matter, 0.54% in the white
matter and 1.71% in the spinal cord.
The dephosphorylated NfH levels were about 5–fold higher in control
spinal cord white matter compared to brain gray matter (p<0.05) or brain
white matter (p<0.05, Table 2 B).
For hyperphosphorylated NfH the bulk of the protein was found in the
control brain white matter (F2,16=6.79, p<0.01) with levels being about 17–
fold above levels in control brain gray matter (p<0.01) and about 10–fold
higher than levels of spinal cord hyperphosphorylated NfH (p<0.01, Ta-
ble 2 A).
Distribution of NfH phosphoforms in MS
Brain gray matter There were no significant differences between con-
trols and MS patients for any of the NfH phosphoforms (Table 2 A and
B).
Brain white matter Significant differences in tissue levels were found
in NAWM, AL and CL, for phosphorylated NfH (F3,20=3.34, p<0.05), hy-
perphosphorylated NfH (F3,20=8.44, p<0.001) and dephosphorylated NfH
(F3,20=5.66, p<0.01). The highest levels of phosphorylated and hyper-
phosphorylated NfH were found in AL (Table 2 A). Significances were con-
firmed on a categorical level by Fisher’s exact test (Figure 6 A and B).
Dephosphorylated NfH was found to be highest in NAWM (Table 2 B, Fig-
ure 7 A).
Spinal cord white matter Significant differences in tissue levels were
found for hyperphosphorylated NfH (F3,24=3.24, p<0.05) and dephospho-
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rylated NfH (F3,24=5.30, p<0.01). Levels of hyperphosphorylated NfH were
significantly higher in AL compared to control tissue (Table 2 A and Fig-
ure 6 D). Dephosphorylated NfH was lowest in CL (Table 2 B and Figure 7
B).
Differences between MS brain and spinal cord The concentration of
phosphorylated NfH was 2 to 8–fold higher in the spinal cord than in the
brain for MS white matter (p<0.01) and CL (p<0.01). In contrast dephos-
phorylated NfH was 7 to 13–fold higher in the brain compared to the spinal
cord white matter (p<0.05) and CL (p<0.05). This was inverse to the pat-
tern observed for dephosphorylated NfH in the control tissue (see above
and Table 2 B).
Image analysis
The electron micrograph of the axonal ultrastructure is shown in Figure8.
The images demonstrate the more disorderly axonal cytoskeleton in NAWM
if compared to control white matter. Additionally, the spacing between the
intermediate filaments is larger suggetive of reduced compactness of Nfs
in NAWM.
Samples from the periventricular control tissue and NAWM of the frontal
periventricular white matter were analysed. A median of 3016 (636–20849)
pixels per axon were examined from slides stained for SMI32 with and
without ALP treatment. The median axonal diameter was 5.8 (3.0–23.3)
pixels. There was a Gaussian distribution for small axons (≤ 10 pixels)
and a bimodal distribution for large axons (data not shown). The median
axonal OD was 81.1 (4.9–283.4, arbitrary units). There was no significant
difference in axonal size between control tissue and NAWM with a median
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diameter of 15 pixels for large and 5.8 pixels for small axons for either
experiment.
Enzymatic dephosphorylation with ALP uniformly affected axonal NfH
compactness. There was a significant difference in the OD between groups
(F3,156=87.15, p<0.0001). The post–hoc analysis showed that the OD
was higher in ALP–treated slides comparing large axons of control tissue
(OD=160.17) with large axons in NAWM (OD=118.74, p<0.001). Also, the
OD of small axons in control tissue (OD=92.74) was higher than in NAWM
(OD=63.65, p<0.01). The OD was consistently higher in all ALP–treated
axons than in untreated axons (p<0.001 for each comparison). This ex-
plains the increase of axonal compactness of NfH after treatment with ALP
in control tissue and NAWM (p<0.001, p=0.001, respectively).
Indeed, axonal compactness of NfH was significantly different between
groups (F3,156=37.76, p<0.001). The post–hoc analysis showed a higher
degree of axonal compactness of NfH in ALP–treated control tissue com-
pared to NAWM axons (p<0.001, Figure 9).
4 Discussion
NfH topography and compactness in control tissue The significant
trend for increasing concentrations of phosphorylated NfH (SMI 35, see
Figure 1) from the brain gray matter to brain white matter to spinal cord
white matter suggests an increase in parenchymal axonal density. These
results are consistent with recently reported findings in rodents.26
In view of the high levels of hyperphosphorylated NfH (SMI 34) in brain
white matter, the finding of a rostro–caudal gradient for dephosphorylated
NfH (SMI 32) needs to be interpreted on basis of the original work on en-
zymatic dephosphorylation by ALP (refer to Figure 1). According to Stern-
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berger et al. ALP either uncovers hidden epitopes by dephosphorylation,21
causes conformational changes, or releases NfH from protein/organelle
binding (i.e. binding to microtubules). It was also suggested that phospho-
rylation increases compactness and order in Nf structure.21 In contrast,
the dephosphorylated forms of Nf are more easily transported along the
microtubule tracks, and the degree of phosphorylation correlated inversely
with the velocity of axonal transport.27
The present findings suggest that the degree of NfH phosphorylation
and compaction may increase from the brain gray matter to white matter
and further to the long tract axons of the spinal cord. We believe this is of
biological relevance as will be seen below.
NfH levels are reduced in chronic lesions Both for brain and spinal
cord tissue the lowest levels of dephosphorylated NfH were found in CL.
This was consistent with the immunocytochemical observation that stain-
ing for dephosphorylated NfH was reduced in CL and its border region.
These findings are in line with the observation of axonal loss in CL.1,2,28
The more marked reduction of dephosphorylated NfH in CL of the spinal
cord compared to the brain, which in fact is the inverse pattern to what we
observed in control tissue, suggests some heterogeneity of the pathologi-
cal process affecting brain and spinal cord axons.
Phosphorylated NfH appeared to “piled up” at the border of the CL
(Figure 4 A–D). This contamination with phosphorylated NfH from the bor-
der region probably explains why in contrast to dephosphorylated NfH no
significant difference was found compared to NAWM.
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NfH phosphorylation is abnormal in NAWM The finding of enzymat-
ically dephosphorylated NfH levels being approximately 7–fold higher in
NAWM compared to control tissue, is corroborated by our immunocyto-
chemical results. This difference is better apreciated from ELISA results,
probably owing to a more effective exposure of epitopes during protein ex-
traction if compared to antibody incubation of the intact tissue slide. This
probably indicates an increase of aberrantly phosphorylated and/or aggre-
gated NfH in brain white matter axons of these patients with secondary
progressive MS. Not only is there an absolute increase of dephosphory-
lated NfH but the electron micrographs and image analysis also suggests
that it is more diffusely distributed within the NAWM axons. Compared
to control tissue axonal compactness of NfH was significantly reduced in
NAWM. Importantly, this was independent of axonal diameter. This find-
ing extends previous observations,21 and suggests post–translational al-
terations of the axoskeleton at early stages of axonal pathology. We note
that because all PM tissue was from patients with secondary progressive
MS it is not possible to say from our data whether changes in NfH phos-
phorylation are a feature at onset of the disease. In order to address this
question future studies may require biopsy material from patients with a
clinical isolated syndrome or early relapsing remmitting MS. Because the
increase of axonal compactness of NfH was only observed after incuba-
tion with ALP, we suggest that epitopes were hidden and/or the protein
was bound, i.e. to microtubules and that initially the epitopes were not ac-
cessible to the SMI32 antibody.
NfH phosphorylation is increased in acute MS lesions The highest
levels of phosphorylated and hyperphosphorylated NfH were found in AL
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(Figure 3). Immunocytochemistry results showed a high amount of stain-
ing for SMI34 and SMI35 in axonal end–bulbs and thick axons bordering
the AL. This suggests a volume-effect of accumulated phosphorylated and
hyperphosphorylated NfH in this region which is greater than the relative
NfH scarcity in the centre of the plaque, but the possibility of an additional
extracellular component also needs to be considered. The existence of
extracellular, mainly aggregated and phosphorylated NfH is known in the
dementia literature (reviewed in10). Extracellular NfH which is not bound
to tangles might be disregarded as non–specific background and thus
escape the immunocytochemical observation. Consistent with one3 but
in contrast to other immunocytochemical observations2,29–32 we were not
able to demonstrate a quantitative difference for hypo–phosphorylated NfH
levels between AL, SAL and CL (data not shown). This may in part be re-
lated to the succeptibility of non-phosphorylated Nf to proteolysis.21,33,34
Is axonal transport in spinal cord axons impaired in MS? The degree
of NfH phosphorylation along the rostro–caudal gradient was substantially
increased in MS if compared to CTRL tissue. Because NfH phosphory-
lation and axonal transport are inversely correlated27,35 this suggests an
impairment of the axonal transport machinery particularly in the long tract
axons of the MS spinal cord. Impaired axonal transport may be an impor-
tant pathological feature to be studies in demyelinating disease because of
the intriguing relationship with dying back neuropathy.36 Dying back neu-
ropathy affects the proximal axon, but does not necessarily require axonal
transsection and also occurs diffusely e.g. in the context of chemotherapy,
mitochondrial dysfunction or axonal Ca–overload. In contrast Wallerian
degeneration affects axonal compartment distal to the lesion.37 In MS
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Wallerian degeneration it thought to be the main mechanism by which ax-
ons degenerate,1–3 a hypothesis supported by brain imaging techniques
investigating axonal tract integrety distal to the lesion site.38 In the CNS
axonal degeneration following injury may be substantiall slower than in the
PNS and take up to several years.37 This is thought to be related to slow
clearance of myelin–asociated inhibitors of axonal growth such as myelin–
associated glycoprotein (MAG), NogoA, oligodendrocyte–myelin glycopro-
tein (OMgp), semaphorin 4D and ephrin B3.37 Unfortunately, our study
was designed to use de–lipidised samples preventing us from further in-
vestigating this exciting hypothesis on the present dataset, but future stud-
ies may be informative. Because Wallerian degeneration is irreversible, but
dying back neuropathy may potentially be prevented it would be extremely
important to try separating these two processes in MS. If as suggested by
the present data dying back neuropathy should be a consistent feature in
the MS CNS tissue then such knowledge could guide the development of
future neuroprotective treatment strategies.
A caveat of this study is that spinal cord tissue was taken only from
patients with SPMS and an EDSS of 9 to 10, likely to represent the “burnt–
out” phase of the disease. On basis of the MRI data, one would have ex-
pected to find severe atrophy in these spinal cords.39 The almost complete
absence of dephosphorylated NfH in CL of the spinal cord also supports
the idea that tissue containing predominantly “burnt–out” axons has been
sampled. Indeed, in patients with primary and secondary progressive MS
we found an increase of phosphorylated and hyperphosphorylated NfH in
the cerebrospinal fluid over a 3–year period.40 An interesting speculation is
that spinal cord axons might differ from brain tissue axons, thus contribut-
ing to the more insidious and inexorable progress of disease once affected.
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One biological explanation for this could be that for “topographical reasons
of function” the spinal cord has to be hostile to axonal sprouting by exploit-
ing the growth–inhibiting properties of proteins as mentioned above, the
inhibition of which may be new neuroprotective strategy in EAE.41 A 20
kDa soluble Nogo–A fragment (an axonal growth inhibitor42) was recently
found to be present in 96% of CSF samples from MS patients, but none of
the control patients.43
Conclusion In summary our data provides evidence that the proportion
of dephosphorylated NfH is increased in MS. Whilst NfH is transported
through the NAWM towards the MS plaque it may become aberrantly phos-
phorylated and/or aggregate and probably slow axonal transport itself. As
NfH reaches the border of the acute plaque and in the spinal cord it be-
comes hyperphosphorylated. Quantification of NfH phosphoforms may
provide a valuable tool to investigate the enzymatic machinery involved in
the dynamics of neuro–axonal degeneration.
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Table 1: Subject characteristics. All data are shown as number (%),
median (range), N.S. = not significant.
Characteristic Controls Multiple sclerosis Significance
Number 15 20
Sex (female:male) 3 (20%) : 12 (80%) 11 (55%) : 9 (45%) p<0.05
Age (yrs) 65 (34–80) 59 (29–77) N.S.
Post–mortem interval (hours) 21 (11–52) 15.5 (4–71) N.S.
Disease duration (yrs) N/A 20 (8–43)
Cause of death
Heart failure 6 (40%) 1 (5%)
Myocardial infarction 4 (27%) 0 (0%)
Bronchopneumonia 2 (13%) 14 (70%)
Pulmonary embolism 1 (7%) 0 (0%)
Sepsis 0 (0%) 3 (15%)
Renal failure 1 (7%) 1 (5%)
Liver carcinoma 1 (7%) 0 (0%)
Bowel carcinoma 0 (0%) 1 (5%)
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Table 2: Brain gray matter, white matter and spinal cord white matter
tissue homogenate levels of (A) phosphorylated/hyperphosphorylated
NfH in tissue homogenate and (B) enzymatically dephosphorylated
NfH. The median value (IQR, n) are shown for normal control white
matter (CTRL), normal–appearing white/gray matter (MS), acute le-
sions (AL) and chronic lesions (CL). The p–values are given if the GLM
allowed for post–hoc analysis, NS = not significant.
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Figure 1: Conformational changes of the NfH protein due to phosphory-
lation expose and hide antibody–binding epitopes. Hyperphosphorylated
NfH is recognised by the antibodies SMI34 and SMI35 and phosphory-
lated NfH by SMI35. Dephosphorylated NfH is strongly recognised by the
antibody SMI32. ALP = alkaline phosphatase.
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A
B
Figure 2: Enzymatic dephosphorylation of purified NfH with ALP. (A) The
Westernblot shows a band for phosphorylated NfH (lane 2) at ≈210 kDa
and for ALP (31 kDa) dephosphorylated NfH (lane 4) at ≈190 kDa. The
immunoblots demonstrate that SMI34 binds selectively to phosphorylated
NfH (lane 5) and SMI32 selectively to ALP dephosphorylated NfH (lane
8). (B) Dephosphorylation of NfH with ALP is dose dependent. Incubation
with ≈ 2mU ALP at 37◦ for 2 hours (pH 10.3) is needed to mask the phos-
phorylated epitopes recognised by the SMI34 (closed line) and unmask
the non–phosphorylated epitopes recognised by SMI32 (dotted line).
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Figure 3: Immunocytochemistry for phosphorylated (SMI35) and dephos-
phorylated (SMI32) NfH in longitudinal sections along axonal trajectories
from normal–appearing white matter [NAWM] far away from any lesion (left
section in the slides), normal–appearing white matter adjacent to the acute
lesion [NAWM (AL), central section in the slides] and the acute lesion [AL,
right section of the slides]. The sections were incubated with (A, C) buffer
only (0.1M Tris-HCl pH 8.0) or (B, D) 100 mU ALP in buffer for 18 hours at
37◦C before immunostaining with either SMI32 or SMI35 (x10).
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Figure 4: Immunocytochemistry of a chronic plaque featuring dephospho-
rylated NfH (A, B) and phosphorylated NfH (C, D). (A, C) show untreated
and (B, D) sections (x10).
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Figure 5: Rostro–caudal gradient of phosphorylated NfH in control tissue
homogenate (mean±SD). There was a significant trend for increasing lev-
els of phosphorylated NfH from brain gray matter to brain white matter to
spinal cord white matter (MHχ2=12.37, p<0.001).
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Figure 6: Tissue homogenate levels of (A) phosphorylated NfH and (B) hy-
perphosphorylated NfH in the brain white matter, (C) phosphorylated and
(D) hyperphosphorylated NfH in the spinal cord white matter. Levels are
shown in µg/mg protein (mean±SD). Levels of significance are indicated
in the graph (Fisher’s exact test) and the cutoff value is shown (dotted line).
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Figure 7: Tissue homogenate levels of dephosphorylated NfH in (A) the
brain white matter and (B) the spinal cord white matter. Levels are shown
in µg/mg protein (mean±SD). Levels of significance are indicated in the
graph (Fisher’s exact test) and the cutoff value is shown (dotted line).
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Figure 8: The ultrastructure of axons from the frontal periventricular white
matter of (A) controls and (B) NAWM from MS patients is shown. The
electron micrographs of several myelinated and unmyelinated axons illus-
trate the more fragmented ultrastructure of axons in NAWM. Additionally
the density of the axonal cytoskeleton is less compact in NAWM axons.
This is best appreciated in the inlay which shows an enlarged copy of two
myelinated and approximately equally sized axons (indicated by a star and
rotated by 90◦ for better visibility). Scale bars 2µm.
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Figure 9: The compactness of axonal NfH is expressed as the ratio of
OD to axonal diameter (mean±SD) as explained in the methods. Com-
pactness of NfH is significantly higher in ALP treated tissue homogenate
from control compared to MS white matter. This effect was not observed
in untreated tissue. Levels of significance are indicated (GLM, post–hoc
analysis, see text).
